Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma
- 9 June 2008
- journal article
- review article
- Published by Elsevier in Seminars in Immunology
- Vol. 20 (5) , 267-275
- https://doi.org/10.1016/j.smim.2008.04.001
Abstract
No abstract availableKeywords
This publication has 171 references indexed in Scilit:
- EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cellsCancer Immunology, Immunotherapy, 2007
- High-throughput oncogene mutation profiling in human cancerNature Genetics, 2007
- Induced sensitization of tumor stroma leads to eradication of established cancer by T cellsThe Journal of Experimental Medicine, 2007
- Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 2006
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- The promise of cancer vaccinesNature Reviews Cancer, 2004
- Saying the ‘S’ word in publicImmunology Today, 1993
- Stereotactic Resection and Its Limitations in Glial NeoplasmsStereotactic and Functional Neurosurgery, 1992
- Randomized Comparisons of Radiotherapy and Nitrosoureas for the Treatment of Malignant Glioma after SurgeryNew England Journal of Medicine, 1980